Probatebeta
Target

CHRM2

Muscarinic acetylcholine receptor M2

As of the edition of 20 October 2026, CHRM2 (muscarinic acetylcholine receptor M2, UniProt P08172) has 16 drugs tested at it and 42 companies on the list, 4 on route A and 10 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P08172
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
17
Disease areas
Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Eye; Mental health; Nervous system; Skin and connective tissue; Immune system
Registered trials of its drugs
565

Drugs at this target

StatusCount
Marketed9
Active1
Went quiet3
Stopped2
Withdrawn from market1
Total16
DrugStatusFurthest phaseUS protection
GlycopyrroniumMarketedPhase 4none listed
AtropineMarketedPhase 4none listed
SolifenacinMarketedPhase 4none listed
TrospiumMarketedPhase 4none listed
FesoterodineMarketedPhase 4none listed
TolterodineMarketedPhase 4none listed
DarotropiumWent quietPhase 2none listed
SofpironiumMarketedPhase 3Ends 2040
BethanecholMarketedPhase 4none listed
TalsaclidineStoppedPhase 3none listed
ASM-024StoppedPhase 2none listed
PT010Went quietPhase 1none listed

12 of 16 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A4
Route B10
Engaged23
Undetermined5
Total on the list42
Three companies on route A or B, with the route only
CompanyRoute
Boehringer IngelheimRoute A
NovartisRoute B
AstellasRoute B

The other 39 companies at CHRM2

In the product

42 companies in all; 39 are not named here, and no score is.

See the 42 companies at CHRM2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at CHRM2

Other targets in urinary and reproductive

Companies holding approvals at CHRM2